1. Home
  2. MANE vs NTLA Comparison

MANE vs NTLA Comparison

Compare MANE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MANE

Veradermics Incorporated Common Stock

N/A

Current Price

$80.18

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$14.94

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MANE
NTLA
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
MANE
NTLA
Price
$80.18
$14.94
Analyst Decision
Strong Buy
Buy
Analyst Count
4
20
Target Price
$78.33
$20.45
AVG Volume (30 Days)
457.0K
2.9M
Earning Date
03-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.92
52 Week Low
$36.26
$6.80
52 Week High
$75.95
$28.24

Technical Indicators

Market Signals
Indicator
MANE
NTLA
Relative Strength Index (RSI) 72.66 63.09
Support Level $54.23 $10.44
Resistance Level N/A $15.51
Average True Range (ATR) 6.51 0.83
MACD 1.12 0.19
Stochastic Oscillator 98.88 90.70

Price Performance

Historical Comparison
MANE
NTLA

About MANE Veradermics Incorporated Common Stock

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: